 sequential intracarotid BCNU cisplatin recurrent malignant glioma authors patients recurrent malignant glioma trial sequential intracarotid BCNU cisplatin Protocol design courses BCNU doses mg cisplatin doses mg intervals Eight patients evaluable first course BCNU partial minor response patients evaluable first course cisplatin evaluable second course BCNU Median survival months range weeks years Cerebral ocular toxicity unique method chemotherapy administration failure clinical improvement common reasons removal study high attrition rate authors unable meaningful response sequential BCNU cisplatin clinical degree cross-resistance agents human malignant glioma